Olaparib丨CAS 763113-22-0

Olaparib丨CAS 763113-22-0
Product Introduction:
Catalog No.: SS127275
CAS No.: 763113-22-0
HPLC assay: 98.0-102.0%
Product Name: Olaparib
Certificate: DMF
Molecular Formula: C24H23FN4O3
Molecular Weight: 434.5
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of olaparib丨cas 763113-22-0 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Appearance: white powder
HPLC assay: 98.0–102.0%
Identification: IR/HPLC
Water: 0.5% max
Residue on ignition: 0.1% max
Ethanol: 0.5% max
Dichloromethane: 0.06% max
Any single impurity: 0.1% max
Total impurity: 0.5% max
Solubility: Slightly soluble in tetrahydrofuran, sparingly soluble in N,N-Dimethylformamide, very slightly soluble in acetonitrile, and practically insoluble in water.
Microbial limit - TAMC: 1000 cfu/g max
Microbial limit - TYMC: 100 cfu/g max
E. coli: Absent per g

 

Transport Information

 

Parameter

Specification

UN Number

2811

Class

6

Packing Group

III

H.S. Code

2933990099306

Stability & Reactivity

The product is chemically stable under standard ambient conditions.

Storage

Tightly closed. Dry. Keep in a well-ventilated place. Keep locked up or in an area accessible only to qualified or authorized persons. Storage stability Recommended storage temperature -20 - 0 °C

Condition to Avoid

 

Package

 

 

Manufacturing Information

 

Parameter

Specification

Capacity

1MT/month

Frequency

 

Main Export Countries

 

Capacity/Batch

 

Experience

Production since 2015

Stock

 

 

 

 

Applications

 

 

1. Targeted Cancer Therapy

Olaparib is a targeted anti-cancer drug used primarily in the treatment of cancers associated with BRCA1/2 gene mutations, including:

Ovarian cancer (especially relapsed or platinum-sensitive)

Breast cancer (HER2-negative, BRCA-mutated)

Prostate cancer (metastatic castration-resistant prostate cancer)

Pancreatic cancer (metastatic BRCA-mutated types)

It's typically used as:

Monotherapy in patients with BRCA mutations

Maintenance therapy following platinum-based chemotherapy

2. Combination Therapy

Olaparib is increasingly being studied and used in combination with other anti-cancer agents such as:

Bevacizumab

Abiraterone

Immune checkpoint inhibitors

These combinations aim to enhance efficacy by attacking cancer through multiple mechanisms.

3. Clinical Trials and Research

Used extensively in:

Clinical research to assess its effectiveness in other tumor types

Exploring its synergy with radiotherapy and DNA-damaging agents

Studying applications in non-BRCA and HRD-positive (homologous recombination deficient) tumors

 

Benefits

 

✅ Targeted Action
Specifically affects cancer cells with defective DNA repair while sparing healthy cells, reducing systemic toxicity.

✅ Prolongs Progression-Free Survival
Significantly improves progression-free survival (PFS) in patients with BRCA-mutant cancers compared to placebo or chemotherapy alone.

✅ Oral Administration
Available as convenient oral tablets, which improves patient compliance and quality of life.

✅ Non-Chemotherapy Option
Provides a non-cytotoxic alternative for long-term maintenance, often delaying the need for more aggressive therapies.

✅ Expanding Indications
Approved for multiple cancer types, and ongoing trials suggest potential broader applicability to other solid tumors.

 

Conclusion

 

Olaparib (CAS 763113-22-0) is a groundbreaking PARP inhibitor that plays a vital role in precision oncology. By exploiting weaknesses in DNA repair pathways of certain cancer cells, it offers effective, targeted treatment for patients with BRCA mutations or HRD-positive tumors. Its growing use in multiple cancer types, favorable administration route, and research potential make it a cornerstone in modern cancer therapeutics.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us